Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
暂无分享,去创建一个
Raimund Erbel | Jörg Barkhausen | J. Barkhausen | R. Erbel | A. Kribben | O. Witzke | U. Hillen | Uwe Hillen | A. Daul | Andreas Kribben | Oliver Witzke | Anton E Daul
[1] Harold I Feldman,et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] Diego R Martin,et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.
[3] Martin R Prince,et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.
[4] M. Panesar,et al. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation , 2008, Clinical transplantation.
[5] A. Molen. NEPHROGENIC SYSTEMIC FIBROSIS AND THE ROLE OF GADOLINIUM CONTRAST MEDIA , 2008 .
[6] J. Penfield. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents , 2008, Pediatric Nephrology.
[7] J. Ranville,et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. , 2008, Kidney international.
[8] S. Cowper,et al. Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.
[9] R. Reilly. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[10] P. Marckmann,et al. Nephrogenic systemic fibrosis: epidemiology update , 2008, Current opinion in nephrology and hypertension.
[11] A. Kribben,et al. Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. , 2008, Minerva Medica.
[12] H. Thomsen,et al. High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.
[13] S. Cowper,et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment , 2008, Seminars in dialysis.
[14] Jane O. Schell,et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future , 2008, Seminars in dialysis.
[15] R. Rodby. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Dialytic Therapies to Prevent NSF Following Gadolinium Exposure in High‐Risk Patients , 2008, Seminars in dialysis.
[16] S. Punwani,et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non‐Gadolinium Options for the Imaging of CKD/ESRD Patients , 2008, Seminars in dialysis.
[17] R. Reilly,et al. What nephrologists need to know about gadolinium , 2007, Nature Clinical Practice Nephrology.
[18] L. Skov,et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] R. Woolson,et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] W. Eubank,et al. Steady‐state free precession MRA of the renal arteries: Breath‐hold and navigator‐gated techniques vs. CE‐MRA , 2007, Journal of magnetic resonance imaging : JMRI.
[21] Sudhir V. Shah,et al. New insights into nephrogenic systemic fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.
[22] L. Chibnik,et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.
[23] M. Reiser,et al. Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie , 2007, Der Radiologe.
[24] H. Thomsen,et al. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? , 2007, Acta radiologica.
[25] Z. Endre. Nephrogenic systemic fibrosis: is any contrast safe in renal failure? , 2007, Internal medicine journal.
[26] John Gosbee,et al. ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.
[27] M. Goyen,et al. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide , 2007, European Radiology.
[28] K. Ballen. Targeting the stem cell niche: squeezing blood from bones , 2007, Bone Marrow Transplantation.
[29] A. Djamali,et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.
[30] S. Cowper,et al. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[31] E. Fleck,et al. Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession , 2007, The International Journal of Cardiovascular Imaging.
[32] S. Morcos. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.
[33] V. Runge,et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.
[34] M. Lucia,et al. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Nature Clinical Practice Nephrology.
[35] Gerald A Kirk,et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.
[36] S. Textor,et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. , 2007, Nephrology, Dialysis and Transplantation.
[37] M. Port,et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.
[38] H. Thomsen. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.
[39] M. Pittelkow,et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. , 2006, Annals of internal medicine.
[40] Yoshiaki Tanaka,et al. Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.
[41] S. Cowper,et al. Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.
[42] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[43] S. Cowper. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[44] R. Elenitsas,et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.
[45] S. Jimenez,et al. Involvement of skeletal muscle in dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy) , 2004, Muscle & nerve.
[46] P. Leboit,et al. Nephrogenic fibrosing dermopathy: two pediatric cases. , 2003, The Journal of pediatrics.
[47] C. Heeschen,et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.
[48] R. Bucala,et al. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.
[49] M. Miyazaki,et al. Peripheral MR angiography: separation of arteries from veins with flow-spoiled gradient pulses in electrocardiography-triggered three-dimensional half-Fourier fast spin-echo imaging. , 2003, Radiology.
[50] R. Swartz,et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.
[51] F. Maes,et al. Improved visualization of coronary arteries using a new three-dimensional submillimeter MR coronary angiography sequence with balanced gradients. , 2002, AJR. American journal of roentgenology.
[52] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[53] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[54] F. S. Pereles,et al. Thoracic aortic dissection and aneurysm: evaluation with nonenhanced true FISP MR angiography in less than 4 minutes. , 2002, Radiology.
[55] P. Leboit,et al. Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.
[56] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[57] S. Swan,et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.
[58] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[59] M. Hunter,et al. Volume-activated, gadolinium-sensitive whole-cell currents in single proximal cells of frog kidney , 1994, Pflügers Archiv.
[60] S. Cowper,et al. Nephrogenic systemic fibrosis: an overview. , 2008, Journal of the American College of Radiology : JACR.
[61] F. Artunc,et al. Nephrogene systemische Fibrose , 2008, Deutsche medizinische Wochenschrift.
[62] A. Rosenkranz,et al. Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? , 2007, Wiener klinische Wochenschrift.
[63] J. Zic,et al. Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.
[64] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[65] N. Liégeois,et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. , 2003, Journal of the American Academy of Dermatology.
[66] D. Cohen,et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.